Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood–brain barrier

Synnøve Nymark Aasen, Heidi Espedal, Christopher Florian Holte, Olivier Keunen, Tine Veronika Karlsen, Olav Tenstad, Zaynah Maherally, Hrvoje Miletic, Tuyen Hoang, Anne Vaag Eikeland, Habib Baghirov, Dag Erlend Olberg, Geoffrey John Pilkington, Gobinda Sarkar, Robert B. Jenkins, Terje Sundstrøm, Rolf Bjerkvig, Frits Thorsen

Research output: Contribution to journalArticle

Abstract

Patients with melanoma have a high risk of developing brain metastasis, which is associated with a dismal prognosis. During early stages of metastasis development, the blood–brain barrier (BBB) is likely intact, which inhibits sufficient drug delivery into the metastatic lesions. We investigated the ability of the peptide, K16ApoE, to permeabilize the BBB for improved treatment with targeted therapies preclinically. Dynamic contrast enhanced MRI (DCE-MRI) was carried out on NOD/SCID mice to study the therapeutic window of peptide-mediated BBB permeabilization. Further, both in vivo and in vitro assays were used to determine K16ApoE toxicity and to obtain mechanistic insight into its action on the BBB. The therapeutic impact of K16ApoE on metastases was evaluated combined with the mitogen-activated protein kinase pathway inhibitor dabrafenib, targeting BRAF mutated melanoma cells, which is otherwise known not to cross the intact BBB. Our results from the DCE-MRI experiments showed effective K16ApoE-mediated BBB permeabilization lasting for up to 1 hour. Mechanistic studies showed a dose-dependent effect of K16ApoE caused by induction of endocytosis. At concentrations above IC50, the peptide additionally showed nonspecific disturbances on plasma membranes. Combined treatment with K16ApoE and dabrafenib reduced the brain metastatic burden in mice and increased animal survival, and PET/CT showed that the peptide also facilitated the delivery of compounds with molecular weights as large as 150 kDa into the brain. To conclude, we demonstrate a transient permeabilization of the BBB, caused by K16ApoE, that facilitates enhanced drug delivery into the brain. This improves the efficacy of drugs that otherwise do not cross the intact BBB.

Original languageEnglish (US)
Pages (from-to)2171-2181
Number of pages11
JournalMolecular cancer therapeutics
Volume18
Issue number11
DOIs
StatePublished - Jan 1 2019

Fingerprint

Neoplasm Metastasis
Peptides
Brain
Pharmaceutical Preparations
Melanoma
Therapeutics
Inbred NOD Mouse
SCID Mice
Protein Kinase Inhibitors
Endocytosis
Mitogen-Activated Protein Kinases
Inhibitory Concentration 50
Molecular Weight
Cell Membrane
dabrafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Aasen, S. N., Espedal, H., Holte, C. F., Keunen, O., Karlsen, T. V., Tenstad, O., ... Thorsen, F. (2019). Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood–brain barrier. Molecular cancer therapeutics, 18(11), 2171-2181. https://doi.org/10.1158/1535-7163.MCT-19-0160

Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood–brain barrier. / Aasen, Synnøve Nymark; Espedal, Heidi; Holte, Christopher Florian; Keunen, Olivier; Karlsen, Tine Veronika; Tenstad, Olav; Maherally, Zaynah; Miletic, Hrvoje; Hoang, Tuyen; Eikeland, Anne Vaag; Baghirov, Habib; Olberg, Dag Erlend; Pilkington, Geoffrey John; Sarkar, Gobinda; Jenkins, Robert B.; Sundstrøm, Terje; Bjerkvig, Rolf; Thorsen, Frits.

In: Molecular cancer therapeutics, Vol. 18, No. 11, 01.01.2019, p. 2171-2181.

Research output: Contribution to journalArticle

Aasen, SN, Espedal, H, Holte, CF, Keunen, O, Karlsen, TV, Tenstad, O, Maherally, Z, Miletic, H, Hoang, T, Eikeland, AV, Baghirov, H, Olberg, DE, Pilkington, GJ, Sarkar, G, Jenkins, RB, Sundstrøm, T, Bjerkvig, R & Thorsen, F 2019, 'Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood–brain barrier', Molecular cancer therapeutics, vol. 18, no. 11, pp. 2171-2181. https://doi.org/10.1158/1535-7163.MCT-19-0160
Aasen, Synnøve Nymark ; Espedal, Heidi ; Holte, Christopher Florian ; Keunen, Olivier ; Karlsen, Tine Veronika ; Tenstad, Olav ; Maherally, Zaynah ; Miletic, Hrvoje ; Hoang, Tuyen ; Eikeland, Anne Vaag ; Baghirov, Habib ; Olberg, Dag Erlend ; Pilkington, Geoffrey John ; Sarkar, Gobinda ; Jenkins, Robert B. ; Sundstrøm, Terje ; Bjerkvig, Rolf ; Thorsen, Frits. / Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood–brain barrier. In: Molecular cancer therapeutics. 2019 ; Vol. 18, No. 11. pp. 2171-2181.
@article{f8548d0ef06241c585d0d2b994a54134,
title = "Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood–brain barrier",
abstract = "Patients with melanoma have a high risk of developing brain metastasis, which is associated with a dismal prognosis. During early stages of metastasis development, the blood–brain barrier (BBB) is likely intact, which inhibits sufficient drug delivery into the metastatic lesions. We investigated the ability of the peptide, K16ApoE, to permeabilize the BBB for improved treatment with targeted therapies preclinically. Dynamic contrast enhanced MRI (DCE-MRI) was carried out on NOD/SCID mice to study the therapeutic window of peptide-mediated BBB permeabilization. Further, both in vivo and in vitro assays were used to determine K16ApoE toxicity and to obtain mechanistic insight into its action on the BBB. The therapeutic impact of K16ApoE on metastases was evaluated combined with the mitogen-activated protein kinase pathway inhibitor dabrafenib, targeting BRAF mutated melanoma cells, which is otherwise known not to cross the intact BBB. Our results from the DCE-MRI experiments showed effective K16ApoE-mediated BBB permeabilization lasting for up to 1 hour. Mechanistic studies showed a dose-dependent effect of K16ApoE caused by induction of endocytosis. At concentrations above IC50, the peptide additionally showed nonspecific disturbances on plasma membranes. Combined treatment with K16ApoE and dabrafenib reduced the brain metastatic burden in mice and increased animal survival, and PET/CT showed that the peptide also facilitated the delivery of compounds with molecular weights as large as 150 kDa into the brain. To conclude, we demonstrate a transient permeabilization of the BBB, caused by K16ApoE, that facilitates enhanced drug delivery into the brain. This improves the efficacy of drugs that otherwise do not cross the intact BBB.",
author = "Aasen, {Synn{\o}ve Nymark} and Heidi Espedal and Holte, {Christopher Florian} and Olivier Keunen and Karlsen, {Tine Veronika} and Olav Tenstad and Zaynah Maherally and Hrvoje Miletic and Tuyen Hoang and Eikeland, {Anne Vaag} and Habib Baghirov and Olberg, {Dag Erlend} and Pilkington, {Geoffrey John} and Gobinda Sarkar and Jenkins, {Robert B.} and Terje Sundstr{\o}m and Rolf Bjerkvig and Frits Thorsen",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-19-0160",
language = "English (US)",
volume = "18",
pages = "2171--2181",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood–brain barrier

AU - Aasen, Synnøve Nymark

AU - Espedal, Heidi

AU - Holte, Christopher Florian

AU - Keunen, Olivier

AU - Karlsen, Tine Veronika

AU - Tenstad, Olav

AU - Maherally, Zaynah

AU - Miletic, Hrvoje

AU - Hoang, Tuyen

AU - Eikeland, Anne Vaag

AU - Baghirov, Habib

AU - Olberg, Dag Erlend

AU - Pilkington, Geoffrey John

AU - Sarkar, Gobinda

AU - Jenkins, Robert B.

AU - Sundstrøm, Terje

AU - Bjerkvig, Rolf

AU - Thorsen, Frits

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Patients with melanoma have a high risk of developing brain metastasis, which is associated with a dismal prognosis. During early stages of metastasis development, the blood–brain barrier (BBB) is likely intact, which inhibits sufficient drug delivery into the metastatic lesions. We investigated the ability of the peptide, K16ApoE, to permeabilize the BBB for improved treatment with targeted therapies preclinically. Dynamic contrast enhanced MRI (DCE-MRI) was carried out on NOD/SCID mice to study the therapeutic window of peptide-mediated BBB permeabilization. Further, both in vivo and in vitro assays were used to determine K16ApoE toxicity and to obtain mechanistic insight into its action on the BBB. The therapeutic impact of K16ApoE on metastases was evaluated combined with the mitogen-activated protein kinase pathway inhibitor dabrafenib, targeting BRAF mutated melanoma cells, which is otherwise known not to cross the intact BBB. Our results from the DCE-MRI experiments showed effective K16ApoE-mediated BBB permeabilization lasting for up to 1 hour. Mechanistic studies showed a dose-dependent effect of K16ApoE caused by induction of endocytosis. At concentrations above IC50, the peptide additionally showed nonspecific disturbances on plasma membranes. Combined treatment with K16ApoE and dabrafenib reduced the brain metastatic burden in mice and increased animal survival, and PET/CT showed that the peptide also facilitated the delivery of compounds with molecular weights as large as 150 kDa into the brain. To conclude, we demonstrate a transient permeabilization of the BBB, caused by K16ApoE, that facilitates enhanced drug delivery into the brain. This improves the efficacy of drugs that otherwise do not cross the intact BBB.

AB - Patients with melanoma have a high risk of developing brain metastasis, which is associated with a dismal prognosis. During early stages of metastasis development, the blood–brain barrier (BBB) is likely intact, which inhibits sufficient drug delivery into the metastatic lesions. We investigated the ability of the peptide, K16ApoE, to permeabilize the BBB for improved treatment with targeted therapies preclinically. Dynamic contrast enhanced MRI (DCE-MRI) was carried out on NOD/SCID mice to study the therapeutic window of peptide-mediated BBB permeabilization. Further, both in vivo and in vitro assays were used to determine K16ApoE toxicity and to obtain mechanistic insight into its action on the BBB. The therapeutic impact of K16ApoE on metastases was evaluated combined with the mitogen-activated protein kinase pathway inhibitor dabrafenib, targeting BRAF mutated melanoma cells, which is otherwise known not to cross the intact BBB. Our results from the DCE-MRI experiments showed effective K16ApoE-mediated BBB permeabilization lasting for up to 1 hour. Mechanistic studies showed a dose-dependent effect of K16ApoE caused by induction of endocytosis. At concentrations above IC50, the peptide additionally showed nonspecific disturbances on plasma membranes. Combined treatment with K16ApoE and dabrafenib reduced the brain metastatic burden in mice and increased animal survival, and PET/CT showed that the peptide also facilitated the delivery of compounds with molecular weights as large as 150 kDa into the brain. To conclude, we demonstrate a transient permeabilization of the BBB, caused by K16ApoE, that facilitates enhanced drug delivery into the brain. This improves the efficacy of drugs that otherwise do not cross the intact BBB.

UR - http://www.scopus.com/inward/record.url?scp=85074378141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074378141&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-19-0160

DO - 10.1158/1535-7163.MCT-19-0160

M3 - Article

C2 - 31467182

AN - SCOPUS:85074378141

VL - 18

SP - 2171

EP - 2181

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 11

ER -